Exelixis partners with Roche to trial cancer combination therapy

The alliance will assess Exelixis’ Cabometyx in combination with Roche’s Tecentriq to treat solid tumours. Credit: skeeze from Pixabay.



  • Exelixis partners with Roche to trial cancer combination therapy